Abstract
Several studies have found that the molecular mechanisms of mitochondrial energy metabolism are impaired in major depressive disorder (MDD). Classic antidepressants and atypical antipsychotics can alter the function of enzymes involved in adenosine triphosphate (ATP) metabolism. Quetiapine is an atypical antipsychotic that, in addition to having a therapeutic benefit in treating MDD, appears to exert antioxidant and neuroprotective effects. Therefore, we aimed to evaluate the acute and chronic effects of quetiapine on the activity of enzyme complexes I to IV of the mitochondrial respiratory chain and creatine kinase (CK) in brain regions involved with MDD. After a single dose or serial injections over 14 days of quetiapine (20, 40, and 80 mg) were administered, isolates from the pre- frontal cortex, hippocampus, amygdala and nucleus accumbens were analyzed for enzyme activity levels. The enzyme activity varied according to the dose, brain region, and acute or chronic dosing protocols. In general, complexes I-III activity was increased, especially after acute administration. Acute administration also increased the activity of complex IV and CK in the amygdala while complex I was inhibited in the prefrontal cortex and nucleus accumbens. These results suggest that quetiapine produces an increase in respiratory chain complex activity, which may be underlying its efficacy against psychiatric disorders and neuronal damage.
Keywords: Quetiapine; antidepressant, energy metabolism, creatine kinase, mitochondrial respiratory chain, depression.
Current Neurovascular Research
Title:Acute and Chronic Treatments with Quetiapine Increase Mitochondrial Respiratory Chain Complex Activity in the Rat Brain
Volume: 12 Issue: 3
Author(s): Zuleide M. Ignacio, Gislaine Z. Reus, Helena M. Abelaira, Stephanie E. Titus, Anelise S. Carlessi, Jaine R. da Luz, Beatriz I. Matias, Livia Bruchchen, Milena Carvalho-Silva, Lara M. Gomes, Joyce Rebelo, Emilio L. Streck and Joao Quevedo
Affiliation:
Keywords: Quetiapine; antidepressant, energy metabolism, creatine kinase, mitochondrial respiratory chain, depression.
Abstract: Several studies have found that the molecular mechanisms of mitochondrial energy metabolism are impaired in major depressive disorder (MDD). Classic antidepressants and atypical antipsychotics can alter the function of enzymes involved in adenosine triphosphate (ATP) metabolism. Quetiapine is an atypical antipsychotic that, in addition to having a therapeutic benefit in treating MDD, appears to exert antioxidant and neuroprotective effects. Therefore, we aimed to evaluate the acute and chronic effects of quetiapine on the activity of enzyme complexes I to IV of the mitochondrial respiratory chain and creatine kinase (CK) in brain regions involved with MDD. After a single dose or serial injections over 14 days of quetiapine (20, 40, and 80 mg) were administered, isolates from the pre- frontal cortex, hippocampus, amygdala and nucleus accumbens were analyzed for enzyme activity levels. The enzyme activity varied according to the dose, brain region, and acute or chronic dosing protocols. In general, complexes I-III activity was increased, especially after acute administration. Acute administration also increased the activity of complex IV and CK in the amygdala while complex I was inhibited in the prefrontal cortex and nucleus accumbens. These results suggest that quetiapine produces an increase in respiratory chain complex activity, which may be underlying its efficacy against psychiatric disorders and neuronal damage.
Export Options
About this article
Cite this article as:
Ignacio M. Zuleide, Reus Z. Gislaine, Abelaira M. Helena, Titus E. Stephanie, Carlessi S. Anelise, da Luz R. Jaine, Matias I. Beatriz, Bruchchen Livia, Carvalho-Silva Milena, Gomes M. Lara, Rebelo Joyce, Streck L. Emilio and Quevedo Joao, Acute and Chronic Treatments with Quetiapine Increase Mitochondrial Respiratory Chain Complex Activity in the Rat Brain, Current Neurovascular Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567202612666150603140912
DOI https://dx.doi.org/10.2174/1567202612666150603140912 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of Neuroprotection by Polyphenols
Current Medicinal Chemistry - Central Nervous System Agents Macrophages in Inflammation
Current Drug Targets - Inflammation & Allergy When Nutraceuticals Reinforce Drugs Side Effects: A Case Report
Current Drug Safety Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils
Current Alzheimer Research Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Current Medicinal Chemistry Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation of 170 Xenobiotics as Transactivators of Human Pregnane X Receptor (hPXR) and Correlation to Known CYP3A4 Drug Interactions
Current Drug Metabolism Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Kappa Opioids, Salvinorin A and Major Depressive Disorder
Current Neuropharmacology Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Editorial [Hot Topic: Drug Addiction and Brain Targets: From Preclinical Research to Pharmacotherapy (Guest Editor: Shafiqur Rahman)]
CNS & Neurological Disorders - Drug Targets Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry Ameliorative Effects of GW1929, a Nonthiazolidinedione PPARγ Agonist,on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury
Current Neurovascular Research Nalmefene: A Novel Drug for an Old Disorder
Current Medicinal Chemistry Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology The Relationship between Life Events and Personality Style to the Development of Depressive and Anxiety Disorders Among Adolescents
Adolescent Psychiatry Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry ‘Hot’ Cognition in Major Depressive Disorder: A Systematic Review
CNS & Neurological Disorders - Drug Targets